Pepscan appoints chief business officer

Michiel Lodder joins the Dutch firm from OctoPlus

Pepscan appoints chief business officer
Pepscan Therapeutics, a Dutch biotech company focused on protein mimicry for the discovery of therapeutics peptides and antibodies, has appointed Michiel Lodder as chief business officer.

Lodder joins the firm from OctoPlus, where he was senior manager business development, responsible for licensing, partnering, and alliance management activities.

Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Lodder’s experience is expected to enable the firm to add to these partnerships.

You may also like

Research & Development

Pepscan Therapeutics signs agreement with Crucell

Partners aim to develop of novel vaccines to combat infectious diseases
Research & Development

Pepscan agrees research collaboration with Tibotec

Will use CLIPS to develop therapeutic peptides
Research & Development

Immunovo secures seed funding from venture capitalists

Signs partnering agreement with Pepscan, which takes minority interest in Immunovo
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
Bavarian Nordic secures four-year UK vaccine supply contract

Bavarian Nordic secures four-year UK vaccine supply contract

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox vaccine, supporting the UK's long-term infectious disease preparedness
Pharmaceutical
Pharma’s silent sustainability risk and the supply chain fix

Pharma’s silent sustainability risk and the supply chain fix

Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
Subscribe now